Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Accumulated Expenses (2022 - 2025)

Coya Therapeutics' Accumulated Expenses history spans 4 years, with the latest figure at $945840.0 for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 616.46% year-over-year to $945840.0; the TTM value through Sep 2025 reached $945840.0, up 616.46%, while the annual FY2024 figure was $1.4 million, 53.31% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $945840.0 at Coya Therapeutics, down from $2.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $3.0 million in Q4 2023 and bottomed at $132015.0 in Q3 2024.
  • The 4-year median for Accumulated Expenses is $835263.5 (2023), against an average of $1.1 million.
  • The largest annual shift saw Accumulated Expenses soared 2088.38% in 2023 before it crashed 73.47% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $135864.0 in 2022, then skyrocketed by 2088.38% to $3.0 million in 2023, then tumbled by 53.31% to $1.4 million in 2024, then crashed by 31.86% to $945840.0 in 2025.
  • Per Business Quant, the three most recent readings for COYA's Accumulated Expenses are $945840.0 (Q3 2025), $2.0 million (Q2 2025), and $1.2 million (Q1 2025).